Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
PSI-6130
Другие языки:

    PSI-6130

    Подписчиков: 0, рейтинг: 0
    PSI-6130
    PSI-6130.svg
    Clinical data
    ATC code
    • none
    Identifiers
    • 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C10H14FN3O4
    Molar mass 259.237 g·mol−1
    3D model (JSmol)
    • C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
    • InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
    • Key:NYPIRLYMDJMKGW-VPCXQMTMSA-N
      (verify)

    PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark. Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B.

    PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128. R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.


    Новое сообщение